Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML
Mina M Tayari, Helena Gomes Dos Santos, Felipe Beckedorff, et al.
Hematological Oncology
|
April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Brian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Cancer
|
September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations
Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
Journal of Hematology & Oncology
|
January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Jorge E Cortes, Gail J Roboz, Maria R Baer, et al.
Leukemia Research
|
November 28, 2017
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study
Ronan T Swords, Diana Azzam, Hassan Al-Ali, et al.
Leukemia Research
|
October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
Ronan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Blood Advances
|
April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Courtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Blood Advances
|
April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study
Harinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
The Journal of Clinical Investigation
|
June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Justin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Blood Advances
|
February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
Stéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML
Mina M Tayari, Helena Gomes Dos Santos, Felipe Beckedorff, et al.
Hematological Oncology
|
April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Brian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Cancer
|
September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations
Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
Journal of Hematology & Oncology
|
January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Jorge E Cortes, Gail J Roboz, Maria R Baer, et al.
Leukemia Research
|
November 28, 2017
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study
Ronan T Swords, Diana Azzam, Hassan Al-Ali, et al.
Leukemia Research
|
October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
Ronan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Blood Advances
|
April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Courtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Blood Advances
|
April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study
Harinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
The Journal of Clinical Investigation
|
June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Justin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Blood Advances
|
February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
Stéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Page
of 4